Anchored Immunotherapy

The Challenge

Despite efforts to develop tumor- targeting therapies, very few are focusing on keeping drugs in the tumor microenvironment once they are there. Rapid clearance limits local drug exposure, which leads to reduced efficacy, increased systemic exposure and potential toxicity, and necessitating frequent administrations.

The Solution

Anchored Immunotherapy involves the use of anchored-drug conjugates to keep highly potent drugs at the tumor site.

Prolonged antitumor immune activation

Minimal systemic side effects from drug leakage

Need for fewer injections to achieve benefit

How Anchored-Drug Conjugates Compare to Antibody-Drug Conjugates

Antibody-Drug Conjugate

  • Antibody-based delivery dependent on tumor antigen
  • Suboptimal linker leads to unpredictable drug release

Anchored-Drug Conjugate

  • Anchored-based delivery independent on tumor antigen
  • Strong linker (binder) allows prolonged retention of drug

Anchored Immunotherapy In Action